Cyclosporine – USA

Cyclosporine – USA

IPR decision: Sep 27, 2019

AIA Review #
Filing Date
Institution Date
Petitioner
Patent
Respondent
Status
IPR2016-01127
06/03/2016
12/08/2016
Mylan
8685930
Allergan, Inc.
Terminated-Dismissed
IPR2016-01128
06/03/2016
12/08/2016
Mylan
8629111
Allergan, Inc.
Terminated-Dismissed
IPR2016-01129
06/03/2016
12/08/2016
Mylan
8642556
Allergan, Inc.
Claims are unpatentable
IPR2016-01130
06/03/2016
12/08/2016
Mylan
8633162
Allergan, Inc.
Claims are unpatentable
IPR2016-01131
06/03/2016
12/08/2016
Mylan
8648048
Allergan, Inc.
Terminated-Dismissed
IPR2016-01132
06/03/2016
12/08/2016
Mylan
9248191
Allergan, Inc.
Terminated-Dismissed
On US’930 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, terminated & instituted respectively.
On US’111 patent, Apotex, Argentum, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, terminated, terminated & instituted respectively.
On US’556 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, terminated & instituted respectively.
On US’162 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, instituted & terminated respectively.
On US’048 patent, Apotex, Famy Care, Teva & Akorn filed IPR petitions which were denied, terminated, instituted & terminated respectively.
On US’191 patent, Famy Care, Teva & Akorn filed IPR petitions which were terminated, instituted & terminated respectively.
US 8,685,930 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a topical ophthalmic emulsion for treating an eye of a human having keratoconjunctivitis sicca, dry eye & or increasing tear production.

US 8,629,111 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a topical ophthalmic emulsion for treating an eye comprising cyclosporin A with certain excipients.
US 8,642,556 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a first topical ophthalmic emulsion for treating an eye comprising cyclosporin A with certain excipients.
US 8,633,162 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a method of treating dry eye disease comprising cyclosporin A with certain excipients.
US 8,648,048 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a method of increasing tear production in the eye comprising cyclosporin A with certain excipients.

US 9,248,191 (Allergan, Inc.; Exp: Aug 27, 2024) – OB listed
Claims a method of treating dry eye disease comprising cyclosporin A with certain excipients.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved